AstraZeneca: mixed results for pancreatic cancer drug

(CercleFinance.com) - AstraZeneca's Lynparza nearly doubled the patients' survival time without progression of their metastatic pancreatic cancer in a phase III trial, the Anglo-Swedish drugmaker said on Monday.


Results from the study showed that Lynparza improved the time without disease progression by a median of 7.4 months for patients treated with Lynparza vs. 3.8 months for those on placebo.

Moreover, 22% of patients receiving Lynparza remained free of disease progression after two years vs. 10% on placebo, the group said.

Pancreatic cancer has the worst survival rate of all most frequent cancers.

AstraZeneca cited "unprecedented results," but investors' reaction was far from being enthusiastic this morning, with the stock currently trading down 1% at 5,777 pence.

"There was no statistical improvement in terms of overall survival, with 18,9 months for Lynparza versus 18,1 months for placebo," one Parisian analyst noted.

Copyright (c) 2019 CercleFinance.com. All rights reserved.